Incyte price target raised to $92 from $88 at Citi

Citi analyst David Lebowitz raised the firm’s price target on Incyte to $92 from $88 and keeps a Buy rating on the shares. Incyte announced positive topline results from its pivotal Phase 3 inMIND trial evaluating Monjuvi as an add-on therapy to lenalidomide plus rituximab in relapsed or refractory follicular lymphoma, achieving its primary endpoint of progress-free survival, the analyst tells investors in a research note. The firm updated its model to reflect Incyte’s and partner Syndax’s recent approval of Niktimvo for the treatment of chronic graft-versus-host disease.